पुनर्संयोजक मानव इंसुलिन उत्पादन

जैव प्रौद्योगिकी फार्मास्युटिकल विनिर्माण से मिलती है

Pharmaceutical & Drug Manufacturing Global Industrial Scale $35 billion

अवलोकन

Recombinant human insulin is produced using genetically engineered Escherichia coli or Saccharomyces cerevisiae that express the human insulin gene. This biotechnological process replaced the previous method of extracting insulin from pig and cow pancreases, providing unlimited supply with reduced immunogenicity. The process involves fermentation, cell lysis, inclusion body solubilization, refolding, enzymatic modification, and multi-step chromatographic purification to produce pharmaceutical-grade insulin.

रासायनिक प्रक्रिया

E. coli expressing proinsulin genes are fermented in large bioreactors. Inclusion bodies containing proinsulin are isolated, solubilized in urea, and the protein is refolded by controlled oxidation. Trypsin and carboxypeptidase B cleave the C-peptide to yield mature insulin, which is purified by reversed-phase and ion-exchange chromatography.

Proinsulin →[Trypsin + Carboxypeptidase B] Insulin (A-chain + B-chain linked by disulfide bonds) + C-peptide

कच्चा माल

  • Glucose (C₆H₁₂O₆) — Corn processing (Carbon source for fermentation)
  • Ammonium sulfate ((NH₄)₂SO₄) — Chemical synthesis (Nitrogen source)
  • Trypsin (enzyme) — Recombinant production (C-peptide cleavage)

अंतिम उत्पाद

  • Recombinant human insulin — Diabetes treatment (>98% purity, multiple analog forms)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Fermentation-based production generates biological waste requiring sterilization before disposal. Chromatographic purification consumes significant water and buffer solutions. However, the environmental impact is far less than animal-sourced insulin which required millions of animal pancreases annually.

सुरक्षा संबंधी विचार

हालिया नवाचार

Insulin analogs (lispro, glargine, aspart) with modified amino acid sequences provide faster or longer-acting profiles.
Cell-free protein synthesis and oral insulin delivery systems are in advanced development stages.

%(name)s में और Pharmaceutical & Drug Manufacturing

आइबुप्रोफेन संश्लेषण — BHC हरित प्रक्रिया

Global Industrial Scale

एमोक्सिसिलिन अर्ध-सिंथेटिक उत्पादन

Global Industrial Scale

किण्वन द्वारा पेनिसिलिन G उत्पादन

Global Industrial Scale

पेरासिटामोल (एसिटामिनोफेन) संश्लेषण

Global Industrial Scale

प्रोटॉन पंप अवरोधकों के लिए ओमेप्राज़ोल संश्लेषण

Global Industrial Scale

मेटफॉर्मिन हाइड्रोक्लोराइड संश्लेषण

Global Industrial Scale

सैलिसिलिक अम्ल के एसिटाइलेशन द्वारा एस्पिरिन संश्लेषण

Global Industrial Scale

Frequently Asked Questions

What industry uses पुनर्संयोजक मानव इंसुलिन उत्पादन?
पुनर्संयोजक मानव इंसुलिन उत्पादन is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in पुनर्संयोजक मानव इंसुलिन उत्पादन?
E. coli expressing proinsulin genes are fermented in large bioreactors. Inclusion bodies containing proinsulin are isolated, solubilized in urea, and the protein is refolded by controlled oxidation. Trypsin and carboxypeptidase B cleave the C-peptide to yield mature insulin, which is purified by rev
What is the economic significance of पुनर्संयोजक मानव इंसुलिन उत्पादन?
पुनर्संयोजक मानव इंसुलिन उत्पादन has a market value of $35 billion.
What is the environmental impact of पुनर्संयोजक मानव इंसुलिन उत्पादन?
Fermentation-based production generates biological waste requiring sterilization before disposal. Chromatographic purification consumes significant water and buffer solutions. However, the environmental impact is far less than animal-sourced insulin which required millions of animal pancreases annua
What raw materials are used in पुनर्संयोजक मानव इंसुलिन उत्पादन?
The main raw materials include: Glucose (C₆H₁₂O₆), Ammonium sulfate ((NH₄)₂SO₄), Trypsin (enzyme).